Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 14, 2018
Pharmacy Choice - News - Over-the-Counter Drugs - November 14, 2018

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 39     Next >>     Go To Page:

11/14/18 - Increased Consumer Risks from Purchasing Erectile Dysfunction Medicine on the Gray Market Exposed in New Research
Bayer and the National Consumers League today released a white paper, Increased Consumer Risk from Erectile Dysfunction Medication Advertised and Sold on the Gray Market, which exposes the dangers to consumers who purchase ED medication from illegal online pharmacies also known as the gray market. The white paper was commissioned by Bayer, and
11/13/18 - Cumberland Pharmaceuticals Reports Third Quarter 2018 Financial Results
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced third quarter 2018 financial results and Company update. Cumberland has a portfolio of eight U.S. Food and Drug Administration approved brands. "Our team has been very busy during the
11/13/18 - DiaMedica Therapeutics in Plymouth files for additional stock offering [Star Tribune (Minneapolis)]
Nov. 13 A Plymouth biopharmaceutical company, DiaMedica Therapeutics Inc., is proposing a stock offering to raise $15 million for the development and commercialization of a new drug to treat neurological and kidney diseases. "We have made significant progress in positioning DM199 to treat patients with stroke and kidney diseases," said Rick Paul
11/13/18 - Enanta Announces that AbbVie's MAVYRET? (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Nave Hepatitis C Patients with Compensated Cirrhosis
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the presentation of new data for AbbVie s pan-genotypic chronic hepatitis C virus treatment, MAVYRET?, in treatment-nave patients with compensated cirrhosis
11/13/18 - FDA Grants Priority Review to Genentech's Tecentriq in Combination with Abraxane for the Initial Treatment of People with PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
Genentech, a member of the Roche Group, today announced the U.S. Food and Drug Administration has accepted the company s supplemental Biologics License Application and granted Priority Review for Tecentriq plus chemotherapy for the initial treatment of unresectable locally advanced or metastatic triple-negative breast cancer in people whose..
11/13/18 - OPTINOSE, INC. - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read this section in conjunction with our unaudited interim consolidated financial statements and related notes included in Part I. Item 1 of this Form 10- Q and our audited consolidated financial statements and related notes thereto and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in o
11/13/18 - TECHCARE CORP. - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
The following discussion provides information which management believes is relevant to an assessment and understanding of our results of operations and financial condition. Additional information concerning factors which could cause differences between forward-looking statements and future actual results is discussed under the heading "Risk...
11/12/18 - FDA seizes food and medical products held under insanitary conditions at an Arkansas grocery warehouse
The U.S. Food and Drug Administration today announced that, on behalf of the agency, the U.S. Marshals Service has conducted a mass seizure of FDA- regulated products that were being held under insanitary conditions in which they were exposed to widespread rodent, insect and live animal infestation. The U.S. Department of Justice filed the complain
11/12/18 - OPKO Health Reports Third Quarter 2018 Financial Results
MIAMI- OPKO Health, Inc. reports financial results and business highlights for the three months ended September 30, 2018. Net loss for the three months ended September 30, 2018 decreased by 23% to $27.7 million or $0.05 a share compared to net loss of $35.9 million or $0.06 per share for the comparable 2017 period. Total revenues improved to $249.8
11/12/18 - Saudi Arabia Pharmaceutical Market Projected to Touch $6 Billion by 2020: The report examines Saudi Arabia pharmaceutical market for the period 20162026. The primary objective of the report is to offer insights on various products such as prescrip
The report examines Saudi Arabia pharmaceutical market for the period 2016 2026. The report begins by defining various economic and healthcare indicators in the country, followed by an overview of dynamics of the Saudi Arabia pharmaceutical market, which includes FMI analysis of key trends, drivers, restraints and opportunities and key players.
11/11/18 - New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients
Novartis announced today results of the landmark PIONEER-HF trial showing that in-hospital initiation of Entresto tablets provided superior benefit compared to enalapril a heart failure medication commonly used in patients with HFrEF who had been stabilized following admission for an acute decompensation heart failure event. 1 Results were.
11/11/18 - ODYSSEY OUTCOMES investigators highlight at AHA that Praluent (alirocumab) Injection was associated with fewer deaths from any cause
PARIS and TARRYTOWN, N.Y., Nov. 11, 2018/ PRNewswire/ New analyses on mortality from the 18,924- patient ODYSSEY OUTCOMES trial were presented at the American Heart Association Scientific Sessions 2018.. Some of these deaths could potentially be prevented, particularly among patients who have already been identified as high risk because they have
11/10/18 - American Lung Association Issues Statement on Approval of Asthma Inhaler
The American Lung Association issued the following statement by Chief Medical Officer Albert Rizzo on the Food and Drug Administration's approval of the Primatene Mist asthma inhaler:. "The new version of the asthma inhaler Primatene Mist, recently approved by the U.S. Food and Drug Administration, will offer suboptimal care for the treatment of a
11/10/18 - FDA Approves Return Of Non-Prescription Asthma Inhaler After 7 Years [Tehran Times (Iran)]
Seven years after it was removed from the market, over-the-counter asthma inhaler Primatene has been approved by the Food and Drug Administration again. Does the agency have any concerns about the product this time? In 2011, popular OTC asthma inhaler Primatene was removed from the market because it had chlorofluorocarbon propellants, a known...
11/10/18 - FDA Seizes Food and Medical Products Held Under Insanitary Conditions at an Arkansas Grocery Warehouse
The U.S. Food and Drug Administration today announced that, on behalf of the agency, the U.S. Marshals Service has conducted a mass seizure of FDA- regulated products that were being held under insanitary conditions in which they were exposed to widespread rodent, insect and live animal infestation. The U.S. Department of Justice filed the complain
11/10/18 - NASH clinical trial presentation and continued revenue growth [Sport360]
-Immuron Limited, an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of many gut mediated diseases, today announced that the IMM-124E NASH clinical study findings will be presented by Professor Arun Sanyal at the American Association for the study of Liver Disease..
11/10/18 - NASH clinical trial presentation and continued revenue growth [Sudan Tribune]
Immuron Limited, an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of many gut mediated diseases, today announced that the IMM-124E NASH clinical study findings will be presented by Professor Arun Sanyal at the American Association for the study of Liver Disease...
11/10/18 - New Research Focusing on OTC Drug Market Growth with Trends, Analysis by Regions, Type, Application, Restraints, and Top Key Players - Global Forecast to 2023: This market research report on OTC Drug Market studied by Category (Vitamin and Dietary Su
New York, NY 11/10/2018 OTC drugs are also known as non-prescription medicines, as these can be availed without prescriptions. OTC medicines are safe if they are administered according to the instructions provided by healthcare professionals. Top Players Profiled in this Report includes, Bayer HealthCare, Herbalife, Johnson&Johnson, Friggs, E
11/9/18 - ACETO CORP - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
CAUTIONARY STATEMENT RELATING TO THE SAFE HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This Quarterly Report contains forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking statements contained in this Quarterly Report may not occur.
11/9/18 - ELITE PHARMACEUTICALS INC /NV/ - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
COMPARED TO THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2017 The following discussion of our financial condition and results of operations for the three and six months ended September 30, 2018 and 2017 should be read in conjunction with our unaudited condensed consolidated financial statements and the notes to those statements that are included...
11/9/18 - FDA approves new version of Primatene Mist for mild asthma
The U.S. Food and Drug Administration has approved a new verison of Primatene Mist, an over-the-counter inhaler for mild asthma. Primatene Mist, the only FDA- approved asthma inhaler available without a prescription in the United States, was taken off the market worldwide in 2011 because it contained chlorofluorocarbon propellants. This new version
11/9/18 - FDA Commissioner Gottlieb Issues Joint Statement on Approval of Primatene Mist
The U.S. Department of Health and Human Services' Food and Drug Administration issued the following joint statement by Commissioner Scott Gottlieb and Janet Woodcock, director of the Center for Drug Evaluation and Research, on the approval of over-the-counter Primatene Mist to treat mild asthma:. "In order for a product to be approved by the FDA f
11/9/18 - FDA Decision to Approve Primatene Mist Endangers Asthma Patients, According to Allergy & Asthma Network and Asthma Community Stakeholders
A group of asthma community stakeholders released a joint statement today expressing deep concern over the Food and Drug Administration's decision to approve Primatene Mist as an over-the-counter treatment for mild, intermittent asthma. Allergy& Asthma Network, American Association for Respiratory Care, American College of Allergy, Asthma& Immuno
11/9/18 - FDA seizes food and medical products held under insanitary conditions at an Arkansas grocery warehouse
The U.S. Food and Drug Administration today announced that, on behalf of the agency, the U.S. Marshals Service has conducted a mass seizure of FDA- regulated products that were being held under insanitary conditions in which they were exposed to widespread rodent, insect and live animal infestation. The U.S. Department of Justice filed the compla
11/9/18 - OPKO Health Reports Third Quarter 2018 Financial Results
OPKO Health, Inc. reports financial results and business highlights for the three months ended September 30, 2018. Net loss for the three months ended September 30, 2018 decreased by 23% to $27.7 million or $0.05 a share compared to net loss of $35.9 million or $0.06 per share for the comparable 2017 period. Total revenues improved to $249.8 mill
Articles(s): 1 - 25 of 39     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415